- Home
- CANF vs TNON Comparison
CANF vs TNON Comparison
Compare CANF & TNON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CANF
- TNON
- Stock Information
- Founded
- CANF 1994
- TNON 2012
- Country
- CANF Israel
- TNON United States
- Employees
- CANF N/A
- TNON N/A
- Industry
- CANF Biotechnology: Pharmaceutical Preparations
- TNON Medical Specialities
- Sector
- CANF Health Care
- TNON Health Care
- Exchange
- CANF Nasdaq
- TNON Nasdaq
- Market Cap
- CANF 9.6M
- TNON 11.5M
- IPO Year
- CANF N/A
- TNON 2022
- Fundamental
- Price
- CANF $0.65
- TNON $1.17
- Analyst Decision
- CANF Strong Buy
- TNON Strong Buy
- Analyst Count
- CANF 2
- TNON 2
- Target Price
- CANF $14.50
- TNON $5.50
- AVG Volume (30 Days)
- CANF 171.1K
- TNON 269.5K
- Earning Date
- CANF 08-26-2025
- TNON 11-12-2025
- Dividend Yield
- CANF N/A
- TNON N/A
- EPS Growth
- CANF N/A
- TNON N/A
- EPS
- CANF N/A
- TNON N/A
- Revenue
- CANF $560,000.00
- TNON $2,947,000.00
- Revenue This Year
- CANF $461.72
- TNON $43.52
- Revenue Next Year
- CANF N/A
- TNON $82.14
- P/E Ratio
- CANF N/A
- TNON N/A
- Revenue Growth
- CANF N/A
- TNON N/A
- 52 Week Low
- CANF $0.63
- TNON $0.85
- 52 Week High
- CANF $3.12
- TNON $7.51
- Technical
- Relative Strength Index (RSI)
- CANF 35.47
- TNON 44.55
- Support Level
- CANF $0.64
- TNON $1.13
- Resistance Level
- CANF $0.68
- TNON $1.26
- Average True Range (ATR)
- CANF 0.02
- TNON 0.07
- MACD
- CANF 0.01
- TNON -0.01
- Stochastic Oscillator
- CANF 41.25
- TNON 26.09
About CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)
Can Fite Biofarma Ltd is an clinical-stage biopharmaceutical company. The company develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases and erectile dysfunction. The company's platform technology utilizes the Gi protein associated A3 adenosine receptor, or A3AR, as a therapeutic target. The company's drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).
About TNON Tenon Medical Inc.
Tenon Medical Inc is a medical device company that has developed a novel, minimally invasive approach to the sacroiliac joint (the SI Joint) using a single, robust, titanium implant for the treatment of the common types of SI Joint disorders that cause lower back pain. The Company is focused on three commercial opportunities; Primary SI Joint procedures, Revision procedures of failed SI Joint implants, and SI Joint fusion adjunct to a spine fusion construct. The company derives the majority of its revenue from sales of The Catamaran System to a limited number of clinicians.